Podcasts about toxicologic pathology

Send us a Text Message.Today my guest is Danielle Brown, a fellow veterinary pathologist, the General Manager at Charles River Laboratories Reno, Nevada, and a pioneer in the use of image analysis for toxicologic pathology. Together, we explored the ever-evolving role of image analysis in preclinical studies and how it enhances, rather than replaces, the expertise of pathologists.This conversation is a deep dive into the intersection of pathology and technology, showcasing how image analysis is revolutionizing preclinical research. We also discuss the future of this technology and its implications for the industry.Join us as we navigate the intricacies of image analysis, share insights on the collaborative process between pathologists and image analysis scientists, and look ahead to the exciting advancements on the horizon.Key Discussion Points:[00:00:00] Introduction and Guest Welcome:Introducing Danielle Brown and her significant contributions to the field of toxicologic pathology.[00:02:46] The Role of Image Analysis in Preclinical Drug Development:Why image analysis is crucial for accurate and efficient evaluations in preclinical studies.[00:03:23] Challenges and Limitations of Visual Analysis:Discussing the limitations of visual analysis and how image analysis overcomes these challenges.[00:08:06] Pathologist and Image Analysis Collaboration:The importance of collaboration between pathologists and image analysis scientists to ensure accurate data interpretation.[00:13:00] Efficiency and Cost of Image Analysis vs. Pathologist Scoring:Comparing the efficiency, cost, and consistency between image analysis and traditional pathologist scoring methods.[00:15:18] Validation and Qualification of Image Analysis Algorithms:The process of validating image analysis algorithms to ensure they meet regulatory standards in a GLP environment.[00:19:54] GLP Compliance and Regulatory Considerations:How Charles River ensures GLP compliance in their image analysis processes, making them suitable for regulatory submissions.[00:23:27] Method Development for Specific Stains and Techniques:Approaching projects that require new method development or specialized procedures.[00:27:46] Future of Image Analysis in Pathology:Danielle's insights into the future of image analysis and how emerging technologies will shape the field.This episode is packed with valuable insights and practical advice for anyone involved in preclinical research or interested in the integration of image analysis in pathology. Danielle's expertise and our discussion provide a roadmap for leveraging image analysis to increase evaluation efficiency and the granularity of your data.THIS EPISODE'S RESOURCES:

Send us a Text Message.This episode was originally recorded for  "People of Pathology Podcast" and I had the pleasure of being interviewed by Dennis Strenk after I have published my book "Digital Pathology 101 - All you need to know to start and continue your digital pathology journey". This was my third appearance on his show, so I was really honored!Our talk about digital pathology focused on the cultural shift and learning mentality essential for embracing rapid advancements in the field. We highlighted the importance of open-mindedness, interdisciplinary collaboration, and the practical applications of AI to enhance diagnostic and workflow processes.I also shared insights from my book, "Digital Pathology 101," which Dennis called "a comprehensive resource for beginners and experts". We covered key topics such as regulatory milestones, interoperability, and the role of toxicologic pathology.CHAPTERSearning Mentality (00:00): Exploring the mindset required for adapting to new technologies in digital pathology.Welcome to the Digital Pathology Podcast (00:53)The Journey of Writing Digital Pathology 101 (02:03): Sharing the process and inspiration behind writing the book.Balancing Content for Different Readers (05:29): How to make the book accessible and valuable for newcomers and seasoned professionals.Digital Pathology Milestones and Surprises (10:27): Highlighting significant achievements and unexpected developments in the field.Interoperability in Digital Pathology (15:19): The importance of systems working together seamlessly.Collaborating with Vendors (17:29): The benefits and challenges of working with technology providers.The Cultural Shift in Digital Pathology (21:47): Emphasizing the need for a cultural change within the pathology community to embrace digital tools fully.AI in Pathology: Narrow vs. General AI (27:17): Differentiating between specific AI applications and broader AI capabilities.Companion Diagnostics and Personalized Medicine (35:34): The role of digital pathology in advancing personalized medicine.The Role of Toxicologic Pathology (38:49): Discussing the role of toxicologic pathology in the digital age.Conclusion and Final Thoughts (42:37): Wrapping up the discussion with reflections and future outlooks.It was great to be Dennis' guest instead of the host this time, and be able to talk about digital pathology and the book to his audience. I liked this episode a lot and I hope you will to.To learn digital pathology fast, be sure to check out my book "Digital Pathology 101." You can get your copy here: Digital Pathology 101 E-book.Watch the full episode hereTHIS EPISODE'S RESOURCESThe original audio version of Dennis' podcast is here:

Toxicologic pathology plays a critical role in drug development, yet its intersection with digital pathology is often overlooked. As a veterinary pathologist, I want to shed light on this important application. This is Chapter 5 of the "Digital Pathology 101" book and in this chapter, you will learn  how whole slide imaging is transforming preclinical trials. I'll explain key concepts like creating faithful digital replicas of glass slides. We'll also dive into validations needs for digital systems in regulated GLP studies.Whole Slide Imaging OverviewI'll start by explaining whole slide imaging. This technology creates 2D digital copies of glass slides. The focus is not 3D images, but flat digital images containing the visual information pathologists need for analysis and reporting.The FDA states these digital images can substitute for glass slides in preclinical toxicity studies, provided they meet requirements as "faithful digital replicas." With proper validations, digital slides enable remote assessments for multisite trials.Validation and DocumentationFor regulated GLP studies, replacing glass slides necessitates validating the whole digital pathology system. This includes IT infrastructure, scanners, software and more based on intended use. Documentation is also key. Peer review statements should note the use of digital slides. Images must be securely stored and transmitted to maintain raw data integrity.ConclusionIn closing, the FDA's guidance on digital pathology in preclinical trials signals an important step towards regulatory acceptance. Digital tools promise more controlled, efficient toxicity assessments, ultimately advancing drug development.This chapter provides a compass for teams navigating digital pathology in regulated environments. Understanding principles of validation, security, and transparency allows us to realize the benefits while ensuring high standards.You can find the original FDA guidance document this chapter is based on here:Use of Whole Slide Imaging in Nonclinical toxicology Studies: Questions & Answers. Or you can watch me explain the guidelines here:What does the FDA Say About Digital Pathology for Nonclinical Toxicology Studies?-------------------------------------------------------Get the PDF of "Digital Pathology 101" Book hereGet the paper copy  of "Digital Pathology 101" on AMAZONWatch the "Digital Pathology 101" Book Launch hereSupport the showSupport the showBecome a Digital Pathology Trailblazer and See you inside the club: Digital Pathology Club Membership

Several scanners have been cleared by the FDA for clinical pathology work, but what about FDAs stand on all the nonclinical pathology work done in a regulatory environment? Specifically the work done in the Good Laboratory Practice (GLP) compliant environment?Can we use the slides without restrictions in lieu of glass slides?What part of the digital pathology system do we need to validate?How do wemaintain and archive the whole slide images used for the pathology portion of the nonclinical toxicologic studies?Good news!There is an official FDA draft guidance for the industry that asks all those and a few more questions and answers them at the same time.In this episode I will go through the guidance for you, so that you don't have to spend time reading this document. But if you feel like doing it anyway, it's available for you to download below in this episode's resources.And in case you want to skip the whole episode (which I sincerely hope you don't! Believe me, it's pretty fun for and FDA guidance episode:), the answer to most questions is YES.Talk to you inside the episode!This episode's resources:Use of Whole Slide Imaging in nonclinical Toxicology Studies: Questions and Answers. Draft Guidance for the Industry.Dr. Aleks Zuraw on TikTok :)And if we are not connected already, let's connect on LinkedIn!

Podcast Editor, Liz McInnes, interviews authors Mark Hoenerhoff to discuss the article, "The Society of Toxicologic Pathology: Advances and Adventures in the First 50 Years" which can currently be found in Vol 49, Issue 8, 2021 of Toxicologic Pathology. Click here to read the article

Podcast Editor, Liz McInnes, interviews authors Hannah Pischon and Valeria Bertani to discuss the article, "Artificial Intelligence in Toxicologic Pathology: Quantitative Evaluation of Compound-Induced Hepatocellular Hypertrophy in Rats" which can currently be found in Vol 49, Issue 4, 2021 of Toxicologic Pathology. Click here to read the article

Podcast Editor, Liz McInnes, interviews authors Renee R. Hukkanen, Armando Irizarry, James D. Fikes and Kenneth A. Schafer to discuss the article, "Opinion on Performing Pathology Peer-Review During the Global Pandemic: Challenges and Opportunities" which can currently be found in Vol 48, Issue 8, 2020 of Toxicologic Pathology. Click here to read the article

Podcast Editor, Charles Wood, interviews author Zaher Radi and Thomas Wynn to discuss the article, "Opinion on Immune Tolerance Therapeutic Development" which can currently be found in Vol. 48, Issue 6 of Toxicologic Pathology. Click here to read the article

I met Chen Sagiv in person in 2019 at the European Congress of Toxicologic Pathology in Cologne, Germany after previously interacting for several months on social media. We stayed in touch ever since and started working on several projects together. Because of her expertise and the great relationship we have developed, she is now my go-to person in the computer vision field. Chen is a mathematician and a computer scientist specialized in computer vision. She is the founder of several tech companies and one of them - DeePathology- has the goal of democratizing pathology. DeePathology's mission is to bring artificial intelligence to pathologists and to make it as easy and as user friendly as possible. DeePathology's software - The Studio - is designed not only to be easy to use for pathologists and life scientists but also to shorten the time required to perform annotations.Annotating structures for training deep learning models is a time consuming and tedious task. By incorporating the principles of active learning into the software the time necessary to generate annotations is significantly reduced. After providing the model with some examples of the structures of interest it starts learning and actively asking the user to review the non-annotated structures recognized by the algorithm. This respect for pathologists' time is something rarely incorporated into digital pathology software design. Digital Pathology Place and DeePathology are hosting a webinar series called "When a Pathologist meets a Mathematician" where we bridge the pathology and computer science concepts. To join our next webinar"The Good, the Bad and the Biased - How can pathologists assess the correctness of AI?" Register hereTo learn more about artificial intelligence register for Chen's free"AI for Pathologists" course hereIn this course, Chen explains the AI principles to pathologists and life scientists who are interested in the subject and want to understand and implement this discipline into their own work.

The guest of this episode is Donal O'Shea, the CEO, and founder of Deciphex. He has been active in the area of digital pathology essentially since its beginning. He worked in academia and founded several successful digital pathology start-ups before his current one.Deciphex, in contrast to most digital pathology companies, is focused on non-clinical pathology, and its mission is to facilitate the complete digitization of this space and to contribute to the faster turnaround time of drug development. The means to achieve these goals are two software products: Patholytix preclinical and Patholytics AI. One of the reasons that the world of toxicologic pathology was lagging behind the world of diagnostic pathology in the digitization efforts was the lack of solutions tailored to this market. Deciphex decided to address all the particularities and nuances of the toxicopathologic workflow through close industry collaborations and by bringing the users to the table during the product development process. This resulted in software that delivers nearly an analog user experience away from the microscope. Non-clinical pathology may seem like a very niche market, but it is one with very high throughput, handling millions of glass slides every year. Accelerating the review of those slides can contribute to tremendous efficiency gains in the pharmaceutical industry. Deciphex is tackling this challenge by enabling organizations to do digital pathology peer reviews of toxicopathologic studies. Pathology peer review is typically connected either with the travel of the peer review pathologists or with the shipment of the slides to them, both of which are time-consuming, costly, could result in glass slide damage and disrupt the normal pathology workflow. All this could be eliminated with a digital workflow, which is extremely desired especially during the COVID-19 pandemic. Digital peer review (and in the long term also digital primary review) can be enabled by the Patholytix preclinical software Another area where Deciphex is focused on helping the pharma industry gain efficiency is artificial intelligence-based generalized abnormality detection in the whole slide images (WSI). This image analysis-based decision support system would flag abnormalities in the WSIs requiring a pathologist review without indicating a diagnosis. This would be of especially great benefit to toxicologic pathology in comparison to diagnostic pathology because most of the slides in a toxicopathologic study are normal. If the review of normal slides could be accelerated by reducing the number of normal slides requiring pathologists' evaluation and allowing them to focus mostly on the abnormal ones the time necessary for study review would decrease tremendously. These improvements would be made possible by the Patholytics AI software as an addition to Patholytix preclinical.To remain agile and responsive to the newest computer vision and digital pathology trends Deciphex products maintain an open framework allowing for experimenting with different current and future AI-models. To learn more about Deciphex and follow their journey visit the Deciphex home page and their LinkedIn and Twitter accounts.

Podcast Editor, Tracy Carlson, interviews author Kristen Hobbie to discuss the article, "Evaluation of Cystic Endometrial Hyperplasia and the Normal Estrous Cycle in Longitudinal Sections of Uterus from Female Harlan Sprague-Dawley Rats" which can currently be found in Vol. 48, Issue 5 of Toxicologic Pathology. Click here to read the article

Podcast Editor, Liz McInnes, interviews author Brad Bolon to discuss the article, "The Exposome in Toxicologic Pathology" which can currently be found in OnlineFirst of Toxicologic Pathology. Click here to read the article

In this podcast, Editorial Board member Elizabeth McInnes invites author Oliver Turner to discuss the article "Society of Toxicologic Pathology Digital Pathology and Image Analysis Special Interest Group Article*: Opinion on the Application of Artificial Intelligence and Machine Learning to Digital Toxicologic Pathology" featured in the Vol 48, Issue 2, 2020 of Toxicologic Pathology. Click here to read the article

In this podcast, Editorial Board member Elizabeth McInnes invites author Renee Hukkanen to discuss the article "The Toxicologic Pathologist’s Role in the 3Rs" featured in the Vol 47, Issue 7, 2019 of Toxicologic Pathology. Click here to read the article

In this podcast, Editorial Board member Elizabeth McInnes invites author Cynthia Willard-Mack to discuss the article "Nonproliferative and Proliferative Lesions of the Rat and Mouse Hematolymphoid System" featured in the August 2019 issue of Toxicologic Pathology. Click here to read the article

In this podcast, Editorial Board member Elizabeth McInnes invites author Janardhan Kyathanahalli to discuss the article "Do GISTs Occur in Rats and Mice? Immunohistochemical Characterization of Gastrointestinal Tumors Diagnosed as Smooth Muscle Tumors in The National Toxicology Program" featured in the July 2019 issue of Toxicologic Pathology. Click here to read the article

In this episode of Causes or Cures, Dr. Erin Stair interviews Dr. Fiorella Belpoggi about the potential health risks of wireless technology and radiation from EMFs (electromagnetic fields). The safety of EMFs is in the news due to the rollout of 5G and because of a recently resurfaced petition to the World Health Organization that was signed by 250 scientists warning about EMF exposure and health effects. Dr. Belpoggi is the head of research at the Ramazzini Institute in Italy and Director of the Cesare Mal-toni Cancer Research Center, where she has worked since 1981. She has published over 100 peer-reviewed papers and has done research on a variety of environmental exposures, including pesticides, plastics, food additives and hormones. To date, she has performed the largest animal study involving EMF ( cell phone) exposure and cancer risk, which is covered in this interview, along with her recommendations for use of cell phones and wireless technology. ( For those with short attention spans, a summary of her recommendations will also be included in Dr. Stair's blog at bloomingwellness.com.) Dr. Belpoggi is a fellow of the International Academy of Toxicologic Pathology; a member of the European Society of Toxicologic Pathology, and she has served as an expert witness or adviser for the European Parliament, the World Health Organization, the Directorate General for Health and Consumer Affairs, and the European Center for Environmental Health. Follow Erin on Instagram Here! To read Dr. Erin Stair's new comedic book on the Wellness Industry, click here: Yours in Wellness, Krystal Heeling.

In this podcast, Editorial Board member Elizabeth McInnes invites author Béatrice Gauthier to discuss the article "Opinion on Integrating Innovative Digital Pathology Tools in the Regulatory Framework" featured in the June 2019 issue of Toxicologic Pathology. Click here to read the article

In this podcast, Editorial Board member Elizabeth McInnes invites author Matt Jacobsen to discuss their article "Opinion on Considerations for the Use of Whole Slide Images in GLP Pathology Peer Review" featured in the February 2019 issue of Toxicologic Pathology. Click here to read the article.

In this podcast, Editorial Board member Elizabeth McInnes invites author Daniel G. Rudmann to discuss their article "The Emergence of Microphysiological Systems (Organs-on-chips) as Paradigm-changing Tools for Toxicologic Pathology" featured in the January 2019 issue of Toxicologic Pathology. Click here to read the article.

In this podcast, Associate Editor Jerrold Ward and author Cynthia Besch-Williford discuss her article "A Naturally Transmitted Epitheliotropic Polyomavirus Pathogenic in Immunodeficient Rats: Characterization, Transmission, and Preliminary Epidemiologic Studies" featured in the July 2017 issue of Toxicologic Pathology.    Click here to read the article. 

In this Toxicologic Pathology podcast, Stacey L. Fossey interviews author Peter Hall on his article "Femoral Head Growth Plate Dysplasia and Fracture in Juvenile Rabbits Induced by Off-target Antiangiogenic Treatment." Epiphyseal growth plate dysplasia (chondrodysplasia) might be considered as the pathognomonic feature of antiangiogenic treatment in preclinical species as it is reliably and dose-responsively induced in rodents and monkeys with vascular endothelial growth factor receptor (VEGFR) inhibitors, fibroblast growth factor (FGF) receptor inhibitors, matrix metalloproteinase inhibitors, and vascular targeting agents. The article suggests that the high prevalence of growth plate fracture in the rabbit may represent a potential additional adverse risk to those already established for children treated with antiangiogenic therapy.

This podcast with Dr. Jeff Wolf discusses the development of a career in the specialized field of fish pathology, and the use of fish in biomedical and environmental research.  As a veterinary pathologist, Dr. Wolf became involved with fish research during his graduate studies and as part of his present job with EPL.  Major uses of fish in toxicology include endocrine disruption research, toxicity screening, assessment of environmental contaminant effects, target animal safety studies (e.g., fish pharmaceuticals), and carcinogenesis research, the last of which was originally prompted by findings of endemic tumors in fish from polluted waters.  Dr. Wolf recently collaborated with 17 other fish pathologists in a Toxicologic Pathology review article that describes and illustrates some common diagnostic misinterpretations evident in the peer-reviewed fish literature, and makes recommendations for improving the quality of papers that publish fish histopathology data.  Dr. Wolf participates in numerous meetings and workshops involving fish toxicology and pathology, and is especially grateful for the opportunity to be able to teach these subjects at Aquavet II, CL Davis courses, and at other domestic and overseas venues.  Click here to read the full article.